NAS:NBIX (USA) Also trade in: Germany UK

Neurocrine Biosciences Inc

$ 85.76 -0.26 (-0.3%)
Volume: 453,088 Avg Vol (1m): 852,247
Market Cap $: 7.85 Bil Enterprise Value $: 7.72 Bil
P/E (TTM): 0.00 P/B: 19.14
Earnings Power Value -6.44
Net Current Asset Value 0.93
Tangible Book 4.5
Projected FCF -2.89
Median P/S Value 209.34
Graham Number 4.5
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 1.33
Cash-To-Debt ranked lower than
77.09% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
NBIX: 1.33
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 1.23, Med: 37.47, Max: 10000
Current: 1.33
1.23
10000
Equity-to-Asset 0.43
Equity-to-Asset ranked lower than
74.71% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
NBIX: 0.43
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.01, Med: 0.78, Max: 0.95
Current: 0.43
0.01
0.95
Debt-to-Equity 0.96
Debt-to-Equity ranked lower than
83.40% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
NBIX: 0.96
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0, Med: 0.13, Max: 16.07
Current: 0.96
0
16.07
Debt-to-EBITDA -120.98
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
NBIX: -120.98
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -120.98, Med: 1.91, Max: 6.89
Current: -120.98
-120.98
6.89
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 7.74
DISTRESS
GREY
SAFE
Beneish M-Score -1.95
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -10.8%
WACC 10.21%

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -5.14
Operating Margin ranked higher than
66.16% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
NBIX: -5.14
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -1730.88, Med: -81.27, Max: 43.82
Current: -5.14
-1730.88
43.82
Net Margin % -7.56
Net Margin ranked higher than
65.53% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
NBIX: -7.56
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -1728.34, Med: -88.19, Max: 48.53
Current: -7.56
-1728.34
48.53
ROE % -9.42
ROE ranked higher than
68.86% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
NBIX: -9.42
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -250.63, Med: -35.17, Max: 94.61
Current: -9.42
-250.63
94.61
ROA % -4.32
ROA ranked higher than
73.62% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
NBIX: -4.32
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -54.01, Med: -24.44, Max: 26.57
Current: -4.32
-54.01
26.57
ROC (Joel Greenblatt) % -22.39
ROC (Joel Greenblatt) ranked higher than
62.36% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
NBIX: -22.39
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -3011.27, Med: -1295.38, Max: 2175.88
Current: -22.39
-3011.27
2175.88
3-Year Total Revenue Growth Rate 183.70
3-Year Revenue Growth Rate ranked lower than
100.00% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
NBIX: 172.4
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: -10.75, Max: 172.4
Current: 172.4
0
172.4

» NBIX's 30-Y Financials

Financials (Next Earnings Date: 2019-07-31)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:NBIX

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325414    SIC : 2836
Compare SZSE:000661 NAS:ALNY NAS:MRNA NAS:TECH HKSE:06160 NAS:JAZZ NAS:BLUE XAMS:GLPG NAS:EXEL NAS:ASND NAS:ARRY TSE:4587 NAS:NKTR NAS:AMRN SZSE:002007 NAS:SRPT NAS:SAGE NAS:IONS SZSE:002252 XBRU:ARGX
Traded in other countries NB3.Germany 0K6R.UK
Address 12780 El Camino Real, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Ratios

Current vs industry vs history
PB Ratio 19.14
PB Ratio ranked lower than
95.11% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
NBIX: 19.14
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 1.35, Med: 10.1, Max: 120
Current: 19.14
1.35
120
PS Ratio 15.55
PS Ratio ranked lower than
68.87% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
NBIX: 15.55
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 3.86, Med: 37.8, Max: 3581.82
Current: 15.55
3.86
3581.82
Price-to-Operating-Cash-Flow 372.36
Price-to-Operating-Cash-Flow ranked lower than
97.62% of 210 companies
in the Biotechnology industry.
Industry Max: 23050, Med: 29.99, Min: 0.04
NBIX: 372.36
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 6.82, Med: 67.59, Max: 819.67
Current: 372.36
6.82
819.67
EV-to-EBIT -958.50
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
NBIX: -958.5
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -1015.4, Med: -19.8, Max: 426.3
Current: -958.5
-1015.4
426.3
EV-to-EBITDA -2374.48
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
NBIX: -2374.48
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -2515.4, Med: -20.3, Max: 293.3
Current: -2374.48
-2515.4
293.3
EV-to-Revenue 14.90
EV-to-Revenue ranked lower than
64.85% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
NBIX: 14.9
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: -3, Med: 27.1, Max: 3853
Current: 14.9
-3
3853
Current Ratio 8.79
Current Ratio ranked higher than
73.93% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
NBIX: 8.79
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.57, Med: 9.63, Max: 26.66
Current: 8.79
1.57
26.66
Quick Ratio 8.61
Quick Ratio ranked higher than
74.77% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
NBIX: 8.61
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.55, Med: 9.63, Max: 26.66
Current: 8.61
1.55
26.66
Days Inventory 431.09
Days Inventory ranked higher than
90.85% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
NBIX: 431.09
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 149.03, Med: 296.4, Max: 443.76
Current: 431.09
149.03
443.76
Days Sales Outstanding 50.65
Days Sales Outstanding ranked higher than
65.42% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
NBIX: 50.65
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 45.49, Med: 57.89, Max: 70.29
Current: 50.65
45.49
70.29
Days Payable 993.96
Days Payable ranked lower than
86.94% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
NBIX: 993.96
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 993.96, Med: 1337.16, Max: 1643.96
Current: 993.96
993.96
1643.96

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -1.70
3-Year Share Buyback Rate ranked higher than
75.61% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
NBIX: -1.7
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -17, Med: -8, Max: -1.3
Current: -1.7
-17
-1.3

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 19.12
Price-to-Tangible-Book ranked lower than
92.51% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
NBIX: 19.12
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 1.11, Med: 5.19, Max: 112.96
Current: 19.12
1.11
112.96
Price-to-Median-PS-Value 0.41
Price-to-Median-PS-Value ranked higher than
61.65% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
NBIX: 0.41
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.1, Med: 0.7, Max: 37.31
Current: 0.41
0.1
37.31
Price-to-Graham-Number 19.18
Price-to-Graham-Number ranked lower than
100.00% of 200 companies
in the Biotechnology industry.
Industry Max: 68.46, Med: 2.27, Min: 0.02
NBIX: 19.18
Ranked among companies with meaningful Price-to-Graham-Number only.
Price-to-Graham-Number range over the past 10 years
Min: 1.17, Med: 1.51, Max: 52.1
Current: 19.18
1.17
52.1
Earnings Yield (Joel Greenblatt) % -0.11
Earnings Yield (Greenblatt) ranked higher than
75.12% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
NBIX: -0.11
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -808.8, Med: -3.1, Max: 1635.4
Current: -0.11
-808.8
1635.4

More Statistics

Revenue (TTM) (Mil) $ 518.56
EPS (TTM) $ -0.48
Beta 1.37
Volatility % 56.06
52-Week Range $ 64.72 - 126.98
Shares Outstanding (Mil) 90.8

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N